Yatharth Hospital & Trauma Care Services Limited (YATHARTH) Fair Value & Analysis
Healthcare · IN · Market cap ₹83.4B
Fair value as of: Jul 3, 2026
From 14 valuation models · updated today
Share price +6.8% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹550.80 – ₹865.55 · fair‑value band ₹270.27 – ₹450.51 · the ₹865.55 price screens above the ₹360.39 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Yatharth Hospital & Trauma Care Services Limited (YATHARTH) currently trades at ₹865.55, while our model-based Fair Value estimate is ₹360.39 — implying the stock looks roughly 58.4% overvalued today. We read business quality at 53/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Yatharth Hospital & Trauma Care Services Limited generated revenue of ₹12.3B at a net margin of 14.2%. Revenue grew 44.2% year over year. It earns a return on equity of 9.9%. Net debt stands at ₹7.3M. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Yatharth Hospital & Trauma Care Services Limited, together with its subsidiaries, owns and operates super-specialty hospitals in India. The company offers services in the areas of medicine, cardiology, neurosciences, general surgery, nephrology and urology, pediatrics, gastroenterology, pulmonology, gynecology, orthopedics, spine and rheumatology, plastic and cosmetic surgery, ear, nose, throat, endocrinology, critical care, dermatology, nuclear medicine, and cancer and bone marrow transplant. It also provides services in the areas of GI surgery and liver transplant, robotic surgery, kidney transplant, IVF and fertility, emergency medicine, ophthalmology, dentistry, psychology and psychiatry, physiotherapy and rehabilitation, anesthesiology, radiology, pathology and laboratory medicine, nutrition and health, interventional spine and pain medicine, neurology, neurosurgery, and cardiovascular and thoracic surgery. In addition, the company sells medicines and canteen food. The company …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Yatharth Hospital & Trauma Care Services Limited reported revenue of ₹12.1B in FY2026 versus ₹4.0B in FY2022, a compound +31.7%/yr. Reported net income was ₹1.8B in FY2026, compounding +41.2%/yr from FY2022.
Is YATHARTH fairly valued? → Check now
Similar stocks
6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc H1CA34 | R$95.75 | R$123.65 | +29% |
| Fresenius SE FSNUY | $11.47 | $8.55 | -25% |
| Q0F Q0F | 2.76 SGD | 1.28 SGD | -54% |
| 5225 5225 | 8.71 MYR | 4.87 MYR | -44% |
| IHHHF IHHHF | $1.71 | $1.17 | -32% |
| Rede D'Or São Luiz S.A RDOR3 | R$32.50 | R$46.04 | +42% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Yatharth Hospital & Trauma Care Services Limited (YATHARTH) undervalued?
What is the fair value of YATHARTH?
What is the quality score of YATHARTH?
What is the revenue of Yatharth Hospital & Trauma Care Services Limited (YATHARTH)?
What is the net profit margin of YATHARTH?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.